A new study shows that prolonging the interval between the first and second dose of COVID-19 vaccines for six to eight weeks has a chance of mitigating the risk of myocarditis/pericarditis and improving vaccine effectiveness. The CDC website published this new update according to the scientists on February 22nd.
The relative case of myocarditis caused by mRNA vaccine is higher in young males ages 12 to 39 years old and claimed this is rare, according to CDC.
The study recommended 3 or 4-week intervals for those who are moderate to severely immunocompromised, 65-year-old and above adults, and those who need rapid protection. This is due to the increased concern about community transmission.
The CDC had released a summary finding of the new study examining international data and policies about their preferential recommendations of an mRNA vaccine product.
Below are the summary findings of each country:
USA: Summary of Findings
Canada: Summary of findings
United Kingdom: Summary of findings
Nordic Countries: Nordic cohort, myocarditis results
Denmark: SARS-CoV-2 vaccination and myocarditis or myopericarditis: a population-based cohort study
France and Germany: Summary of findings
According to the summary of findings, the risk of myocarditis may be higher for Moderna than the Pfizer vaccine.
The study concluded that myocarditis and pericarditis may be associated with Moderna vs. Pfizer especially in males aged 18-29 years old and also with shorter primary series intervals.
Well, it’s too late for this study, billions of test vaccines were already given and now they are saying to extend the interval between shots or you could face myocarditis.
Sources: The Gateway Pundit, CDC
Leave a Comment